Table 1.
Baseline clinical characteristics
| NPR on aspirin (n = 1240) | HPR on aspirin (n = 91) | P value | NPR on clopidogrel (n = 891) | HPR on clopidogrel (n = 437) | P value | |
|---|---|---|---|---|---|---|
| Age, yrs | 64.19 ± 10.06 | 65.63 ± 9.75 | 0.189 | 63.96 ± 10.23 | 64.98 ± 9.60 | 0.082 |
| Male, n (%) | 936 (75.5) | 67 (73.6) | 0.706 | 692 (77.7) | 310 (70.9) | 0.008 |
| BMI, kg/mm2 | 24.70 ± 3.01 | 24.55 ± 3.01 | 0.649 | 24.65 ± 2.95 | 24.78 ± 3.12 | 0.449 |
| Hypertension, n (%) | 888 (71.6) | 66 (72.5) | 0.905 | 644 (72.3) | 307 (70.3) | 0.438 |
| Hyperlipidemia, n (%) | 318 (27.4) | 23 (25.6) | 0.806 | 236 (28.3) | 105 (25.4) | 0.281 |
| Diabetes, n (%) | 328 (26.5) | 24 (26.4) | NS | 239 (26.8) | 112 (25.6) | 0.691 |
| Current smoking, n (%) | 482 (39.2) | 33 (36.7) | 0.656 | 356 (40.3) | 159 (36.7) | 0.229 |
| ACS, n (%) | 1072 (86.5) | 75 (82.4) | 0.272 | 782 (87.8) | 362 (82.8) | 0.018 |
| eGFR < 60 ml/min/1.73 m2, n (%) | 122 (10.1) | 8 (9.2) | NS | 94 (10.9) | 36 (8.4) | 0.170 |
| Prior stroke, n (%) | 138 (11.2) | 11 (12.2) | 0.731 | 93 (10.5) | 56 (12.9) | 0.196 |
| Prior PCI, n (%) | 236 (19.2) | 15 (16.7) | 0.676 | 161 (18.2) | 89 (20.6) | 0.331 |
| LVEF, % | 59.80 ± 9.33 | 58.50 ± 9.89 | 0.275 | 59.59 ± 9.27 | 59.94 ± 9.61 | 0.587 |
| hsCRP, ug/ml | 31.94 ± 8.88 | 32.84 ± 9.16 | 0.400 | 31.98 ± 8.80 | 32.13 ± 9.11 | 0.804 |
| Agents in hospital | ||||||
| Aspirin, 100 mg/d | 1216 (98.1) | 90 (98.9) | NS | 881 (98.9) | 428 (97.9) | 0.218 |
| Clopidogrel, 75 mg/d | 1203 (97.0) | 88 (96.7) | 0.751 | 863 (96.9) | 426 (97.5) | 0.606 |
| Agents at 2 years | ||||||
| Aspirin (100 mg/d), n (%) | 1142 (92.1) | 81 (89.0) | 0.317 | 800 (89.8) | 398 (91.1) | 0.493 |
| Clopidogrel (75 mg/d), n (%) | 806 (65.0) | 57 (62.6) | 0.650 | 570 (64.0) | 266 (61.9) | 0.277 |
BMI body mass index, ACS acute coronary syndrome, eGFR estimated glomerular filtration rate, PCI percutaneous coronary intervention, LVEF left ventricular ejection fraction, hsCRP high sensitivity C reactive protein, NPR normal platelet reactivity, HPR high platelet reactivity